AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01470612
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tablets, BID, for at least 12 months
Trial: NCT01470612
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tablets, BID, for at least 12 months
Trial: NCT01506908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active
Trial: NCT02980250
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Trial: NCT02980250
Drug: normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Trial: NCT02605798
Drug: Elbanovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 400 mg sofosbuvir
Trial: NCT00591331
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01197157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
Trial: NCT01393457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT02197026
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02197026
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug treatment at the discretion of the investigator
Trial: NCT04531657
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
Trial: NCT02283450
Drug: Qiliqiangxin Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04352465
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
Trial: NCT04352465
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
Trial: NCT04352465
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
Trial: NCT00208117
Drug: Simvastatin (Zocor)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
Trial: NCT00988936
Drug: [F-18]RGD-K5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
Trial: NCT04147819
Drug: BAY2701439
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
Trial: NCT03407118
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT03399318
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments
Trial: NCT03399318
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
Trial: NCT03399318
Drug: placebo for acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo
Trial: NCT03399318
Drug: placebo for ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for ibuprofen
Trial: NCT01484184
Drug: SPINALON (buspirone + levodopa + cardidopa)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
Trial: NCT03511170
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
Trial: NCT04632706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to the Active IMP.
Trial: NCT00551382
Drug: Muntelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets or granules; 4 mg once a day for 12 weeks
Trial: NCT01246362
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
Trial: NCT02212340
Drug: fresofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
Trial: NCT02212340
Drug: desflurane and remifentanil
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
Trial: NCT01093807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 10 weeks
Trial: NCT02689063
Drug: Maxigesic IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Trial: NCT02689063
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Trial: NCT02689063
Drug: IV Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Trial: NCT02689063
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
Trial: NCT00350155
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02147249
Drug: antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
Trial: NCT02172352
Drug: Ba 679 BR low dose
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172352
Drug: Ba 679 BR middle dose
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172352
Drug: Ba 679 BR high dose
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172352
Drug: Placebo inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00257920
Drug: Zemplar® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mcg QOD
Trial: NCT00257920
Drug: Hectorol® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mcg QOD
Trial: NCT02744131
Drug: Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate
RxNorm normalized name: cyproterone / ethinyl estradiol Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03043560
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill daily for 5 weeks
Trial: NCT00773695
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
Trial: NCT00773695
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Trial: NCT01117766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID dosing for 28 days
Trial: NCT02429934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02554734
Drug: levodopa, carbidopa, ODM-104
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02554734
Drug: levodopa, carbidopa, entacapone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04248348
Drug: Low Molecular Weight Heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
Trial: NCT01564459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching compressed tablets, taken once daily at bedtime for 14 days.
Trial: NCT00366041
Drug: Dermal substrate cellularised LG002 (10x10cm)
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application depending on burn injury surface
Trial: NCT03443518
Drug: Normal saline 0.9% IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
Trial: NCT03443518
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
Trial: NCT04637633
Drug: topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical preservative free artificial tears Q.I. D.
Trial: NCT01613950
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
Trial: NCT03380559
Drug: Injection, botulinum toxin + corticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)
Trial: NCT03380559
Drug: Injection, placebo of toxin + corticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)
Trial: NCT03380559
Drug: Injection, botulinum toxin + placebo corticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)
Trial: NCT02217631
Drug: Prednisolone low dose
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02217631
Drug: Prednisolone high dose
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02217631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04078438
Drug: treatment as usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
Trial: NCT00794976
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00330564
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
Trial: NCT00372112
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW642444H
Trial: NCT03119974
Drug: Tpo-RA discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
Trial: NCT02037165
Drug: Placebo to BI 1026706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT02037165
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib hard capsule
Trial: NCT02776514
Drug: Suplasyn1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02776514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01244061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo twice daily
Trial: NCT00940797
Drug: DMMET-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
Trial: NCT00940797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
Trial: NCT01370486
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: melatonin cp 2 mg 1x/d for 1 month
Trial: NCT01370486
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cp 1x/d for 1 month
Trial: NCT00642460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv every 2 weeks for 12 weeks
Trial: NCT00788593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
Trial: NCT00766155
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT02040311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00642460
Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT00642460
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: as prescribed
Trial: NCT00642460
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, as prescribed
Trial: NCT02340221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
Trial: NCT06451393
Drug: Neoadjuvant chemotherapy with radical tumor resection surgery
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
Trial: NCT03256422
Drug: Treatment discontinuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir
Trial: NCT02608710
Drug: RDEA3170 4.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00103402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003598
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00794482
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
Trial: NCT02608710
Drug: RDEA3170 6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02608710
Drug: RDEA3170 12 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04013113
Drug: Haemoperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required.
Trial: NCT04013113
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Trial: NCT02677259
Drug: 17-beta estradiol
RxNorm normalized name: 17-beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01733147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
Trial: NCT01436565
Drug: SAR245408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT03168321
Drug: IDP-123 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.045% Lotion
Trial: NCT02563821
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01088919
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00683982
Drug: Probiotic mix preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation 1 gram twice a day for 5 days
Trial: NCT01663727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00375492
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, volume equivalent to exenatide dose, twice a day
Trial: NCT01449045
Drug: Community Case Management with artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
Trial: NCT01790035
Drug: LGG
RxNorm normalized name: LGG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01790035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04891965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
Trial: NCT00004748
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03575871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Trial: NCT02818387
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
Trial: NCT01045993
Drug: marketed analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 200 mg ibuprofen tablets
Trial: NCT01045993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x placebo tablets